2 unknown, 1 completed, 1 withdrawn. 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Lipoproteinemia: new trials by email Literature Review of Lipoproteinemia trials Research Report on Lipoproteinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA) Pelacarsen (TQJ230), Placebo - Acute Coronary Syndrome, Lipoproteinemia | Not applicable | Withdrawn | University Medical Centre Ljubljana | 2021-10-01 | 2022-01-03 | |
| Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment Alirocumab, Evolocumab, Control group - Acute Coronary Syndrome, Premature Coronary Heart Disease | Not applicable | Unknown | University Medical Centre Ljubljana | 70 | 2020-11-10 | 2020-11-03 |
| Kinetic Study of Lp(a) and PCSK9 in Humans infusion of tracer [5,5,5-2H3] -L-leucine - Cholesterol; Metabolic Disorder, Lipoproteinemia | Not applicable | Completed | Nantes University Hospital | 21 | 2020-07-31 | 2022-02-23 |
| Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA) Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV), Lipid filtration (Octo Nova®, Diamed Medizintechnik), Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius) - Lipoproteinemia, Apheresis Related Complication | Unknown | Technische Universität Dresden | 500 | 2014-10-01 | 2022-01-10 |
Acute Coronary Syndrome (2) · Coronary Disease (2) · Dyslipidemias (2) · Inflammation (2) · Cardiovascular Diseases (1) · Metabolic Diseases (1)
Nutritional and Metabolic Diseases (3) · Cardiovascular Diseases (2) · Heart Diseases (2) · Lipid Metabolism Disorders (2) · Metabolic Diseases (2) · Myocardial Ischemia (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Vascular Diseases (2)
Control Groups (1) · Leucine (1) · alirocumab (1) · evolocumab (1) · pelacarsen (1)
University Medical Centre Ljubljana (2) · Nantes University Hospital (1) · Technische Universität Dresden (1)
Slovenia (2) · France (1) · Germany (1)
Andreja Rehberger Likozar, MD (1)